{"doi":"10.1016/j.endmts.2020.100072","title":"Evaluation of healthcare for transgender veterans","abstract":"To identify the cohort of veterans diagnosed with gender dysphoria obtaining care through VA Northern California Healthcare System (VANCHCS), and evaluate their care. Using ICD-10 criteria, we identified veterans with a diagnosis of gender dysphoria. We stratified these individuals by self-identified gender, and evaluated their medical records for gender affirming-hormone therapy and access to behavioral health, endocrine, speech pathology, and dermatology resources. Of the 148 Veterans found, 95 identified as transwomen, 43 as transmen, and 10 as non-binary. Non-binary Veterans were excluded from further analysis. Transmen were significantly younger than transwomen (42±13.7 vs 51.5±15.9 yrs., p< 0.001 by t-test). Transwomen were more likely to be Air Force Veterans than transmen (21.1% vs 17.1%), and less likely to be Army Veterans (38.9% vs 43.9%), but were more likely to see a Endocrinologist (83.2% vs 72.1%) and Speech Therapist (44.2% vs. 25.6%). Gender affirming hormone therapy for transwomen included combinations of gonadotropin-releasing hormone analogs, spironolactone, finasteride, estradiol, and progesterone, whereas for transmen, testosterone was the sole therapy. The majority of our Veterans (65 transwomen (68.4%) and 38 transmen (88.4%) had not undergone gender-affirming surgery. Only 59 transwomen (62%) had measurements of prostate-specific antigen (PSA). Both groups were followed comparably in Behavioral Health Clinics (87.4% for transwomen, 90.7% for transmen). Only 35 transwomen (36.8%) were seen in Dermatology clinics for gender specific needs. Our patients and their management were diverse. We conclude that care for transgender Veterans could be enhanced by a more consistent, team-based approach to therapy.","journal":"Endocrine and Metabolic Science","year":2020,"id":109122,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.6093,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":521775,"name":"Scott Gale","orcid":null,"position":1,"is_corresponding":false},{"id":521208,"name":"Tara M. Neavins","orcid":"0000-0003-4337-7388","position":2,"is_corresponding":false},{"id":521776,"name":"Martha G. Stassinos","orcid":null,"position":3,"is_corresponding":false},{"id":521777,"name":"Rachel E. Tarro-Zylema","orcid":null,"position":4,"is_corresponding":false},{"id":521778,"name":"Bryan D. Volpp","orcid":null,"position":5,"is_corresponding":false},{"id":326814,"name":"Machelle Wilson","orcid":"0000-0003-1734-2755","position":6,"is_corresponding":false},{"id":521209,"name":"Arthur Swislocki","orcid":"0000-0002-1909-7944","position":7,"is_corresponding":false},{"id":521774,"name":"Rachel T. Agron","orcid":null,"position":0,"is_corresponding":true}],"reference_count":27,"raw_metadata":null,"created_at":"2026-07-18T23:12:46.854423Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}